Prostate Cancer and Cardiovascular Risk: Do Routine Specialist Referrals Help?

Prostate Cancer and Cardiovascular Risk Intersection

When men receive a prostate cancer diagnosis, metabolic and cardiovascular risk factors are frequently present, particularly given the advanced age of many patients. Androgen deprivation therapy, a mainstay treatment that suppresses male hormones to slow tumor growth, is known to associate with an increased incidence of diabetes, hypertension, and heart disease. According to an American analysis cited by the study authors, among patients with non-metastatic prostate cancer, 23% of deaths stem from cardiovascular disease, while 17% result from the prostate carcinoma itself. Recognizing this competing mortality risk, researchers designed a pragmatic trial to test whether systematic specialist intervention could improve patient outcomes.

The RADICAL PC2 Trial Design and Interventions

The RADICAL PC2 trial evaluated 2,487 men with a mean age of 68 across 55 centers in eight countries. Participants had either received a prostate cancer diagnosis within the previous year or were about to begin or had just begun androgen deprivation therapy, with 45% already receiving or having received hormone treatment. Researchers randomized the participants into two distinct study arms to test routine care against proactive multidisciplinary management.

• Control Group: Continued receiving standard clinical care without systematic specialist redirection.
• Intervention Group: Referred systematically to a specialist focused on modifying diet, exercise, and smoking habits. Specialists were instructed to prescribe a statin regardless of baseline cholesterol and to add an anti-hypertensive medication when systolic blood pressure exceeded 130 mmHg.

Laboratory Improvements Versus Clinical Event Rates

The systematic referral protocol successfully altered clinical processes and laboratory markers during the observation window. According to the trial data, 90% of men in the intervention arm met with a specialist, compared to just 21% in the usual-care group. By the end of the study, statin usage reached 63% in the intervention group versus 40% in the control group, while anti-hypertensive use stood at 56 and 49%, respectively. Total cholesterol dropped by an average of 12 mg/dL among patients sent to the specialist, accompanied by proportional decreases in LDL and triglycerides. Blood pressure improvements, however, remained modest and inconsistent.

Despite a win ratio of 1.60 favoring the intervention on the hierarchical primary endpoint, the net advantage derived from improved cholesterol management rather than a demonstrated drop in heart attacks, strokes, or deaths. After a median follow-up of 5.8 years, 171 participants—representing a fraction of the cohort—experienced at least one major adverse cardiovascular event, defined as cardiovascular death, myocardial infarction, stroke, or heart failure. The adjusted hazard ratio (sHR) was 1.08, with a confidence interval ranging from 0.79 to 1.49, revealing no statistically significant difference between the two study arms.

Implications for Oncology Care Pathways

Study authors noted that cardiovascular events occurred far less frequently than anticipated, leaving the trial underpowered to definitively confirm a divergence in hard endpoints such as myocardial infarction, stroke, and mortality. Furthermore, contamination occurred as some control group participants independently consulted specialists, and statins were occasionally proposed to patients across widely varying risk profiles. Consequently, researchers recommend a targeted rather than universal approach, suggesting that specialist cardiovascular consultations should be concentrated on prostate cancer patients who present with poorly controlled metabolic risk factors.